Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes

NCT06385327 is registered in ClinicalTrials.gov with Assembly Biosciences as lead sponsor.

NCT NCT06385327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06385327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
Lead sponsor
Assembly Biosciences
Phase
Phase 1
Overall status
Completed
Start date
May 30, 2024
Completion date
February 3, 2026
Enrollment
115 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent genital herpes simplex type 2